methyl 3-methyl-2-(2-(4-nitrophenyl)thiazole-4-carboxamido)butanoate | 1287753-46-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 3-methyl-2-(2-(4-nitrophenyl)thiazole-4-carboxamido)butanoate
• 英文别名: (S)-methyl 3-methyl-2-(2-(4-nitrophenyl)thiazole-4-carboxamido)butanoate；methyl (2S)-3-methyl-2-[[2-(4-nitrophenyl)-1,3-thiazole-4-carbonyl]amino]butanoate
• CAS: 1287753-46-1
• 化学式: C₁₆H₁₇N₃O₅S
• 分子量: 363.394
• InChiKey: KNXLKOLZYBESBL-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  142
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  methyl 3-methyl-2-(2-(4-nitrophenyl)thiazole-4-carboxamido)butanoate 在 水 、 铁粉 、 氯化铵 、 lithium hydroxide 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 40.0h， 生成 2-(2-(4-((6-fluorobenzo[d]thiazol-2-yl)amino)phenyl)thiazole-4-carboxamido)-3-methylbutanoic acid
  参考文献：
  名称：

  Evaluation of thiazole containing biaryl analogs as diacylglycerol acyltransferase 1 (DGAT1) inhibitors

  摘要：

  Biphenyl carboxylic acids, exemplified by compound 5, are known potent inhibitors of diacylglycerol acyltransferase, DGAT1, an enzyme involved in the final committed step of triglyceride biosynthesis. We have synthesized and evaluated 2-phenylthiazole, 4-phenylthiazole, and 5-phenylthiazole analogs as DGAT1 inhibitors. The 5-phenylthiazole series exhibited potent DGAT1 inhibition when evaluated using an in vitro enzymatic assay and an in vivo fat tolerance test in mice. Compound 33 (IC50 = 23 nM) exhibiting promising oral pharmacokinetic parameters (AUC(inf) = 7058 ng*h/ml, T-1/2 = 0.83 h) coupled with 87 percent reduction of plasma triglycerides in vivo may serve as a lead for developing newer anti-obesity agents. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.05.006
• 作为产物：
  描述：

  对硝基苯甲酰胺 在 劳森试剂 、 水 、 三乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 34.0h， 生成 methyl 3-methyl-2-(2-(4-nitrophenyl)thiazole-4-carboxamido)butanoate
  参考文献：
  名称：

  Evaluation of thiazole containing biaryl analogs as diacylglycerol acyltransferase 1 (DGAT1) inhibitors

  摘要：

  Biphenyl carboxylic acids, exemplified by compound 5, are known potent inhibitors of diacylglycerol acyltransferase, DGAT1, an enzyme involved in the final committed step of triglyceride biosynthesis. We have synthesized and evaluated 2-phenylthiazole, 4-phenylthiazole, and 5-phenylthiazole analogs as DGAT1 inhibitors. The 5-phenylthiazole series exhibited potent DGAT1 inhibition when evaluated using an in vitro enzymatic assay and an in vivo fat tolerance test in mice. Compound 33 (IC50 = 23 nM) exhibiting promising oral pharmacokinetic parameters (AUC(inf) = 7058 ng*h/ml, T-1/2 = 0.83 h) coupled with 87 percent reduction of plasma triglycerides in vivo may serve as a lead for developing newer anti-obesity agents. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.05.006

文献信息

• [EN] OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS<br/>[FR] DÉRIVÉS D'OXAZOLE, D'OXADIAZOLE ET DE THIAZOLE COMME INHIBITEURS DE LA DIACYLGLYCÉROL ACYLTRANSFÉRASE
  申请人：PIRAMAL LIFE SCIENCES LTD

  公开号：WO2010023609A1

  公开（公告）日：2010-03-04

  The present invention relates to isoxazole, thiazole and oxidiazole derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, in particular to the use of these compounds in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransf erase (DGAT), particularly DGATl.

  本发明涉及异恶唑、噻唑和氧代唑衍生物，它们的制备方法，含有它们的药物组合物以及它们作为药物的用途，特别是这些化合物在通过二酰基甘油酰转移酶（DGAT）介导的疾病或紊乱的预防和治疗中的应用，特别是DGAT1。
• DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
  申请人：GANGOPADHYAY Ashok Kumar

  公开号：US20110196002A1

  公开（公告）日：2011-08-11

  The present invention relates to isoxazole, thiazole and oxidiazole derivatives, processes for their preparation, pharmaceutical compositions containing them and their use as medicaments, in particular to the use of these compounds in the prevention and treatment of diseases or disorders mediated by diacylglycerol acyltransferase (DGAT), particularly DGAT1.

  本发明涉及异噁唑、噻唑和氧杂唑衍生物，其制备方法，含有它们的药物组合物以及它们作为药物的用途，特别是这些化合物在预防和治疗由二酰基甘油酰转移酶（DGAT）介导的疾病或疾病中的使用，特别是DGAT1。
• US8835428B2
  申请人：——

  公开号：US8835428B2

  公开（公告）日：2014-09-16